FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joep Killestein

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Bob W van Oosten; Frederik Barkhof; Joep Killestein; Chris H Polman; Mike P Wattjes
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
Anke Vennegoor; Gertjan Wolbink; Lisanne J Balk; Frederik Barkhof; Chris H Polman; Theo Rispens; Alexandra Seewann; Eva Mm Strijbis; Bernard Mj Uitdehaag; Joep Killestein
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Lisanne J Balk; Joep Killestein; Chris H Polman; Bernard M J Uitdehaag; Axel Petzold
Microcystic macular oedema confirmed, but not specific for multiple sclerosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joep Killestein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Bob W van Oosten; Frederik Barkhof; Joep Killestein; Chris H Polman; Mike P Wattjes
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
The New England journal of medicine 2013;368(17):1658-9.
2013: Anke Vennegoor; Gertjan Wolbink; Lisanne J Balk; Frederik Barkhof; Chris H Polman; Theo Rispens; Alexandra Seewann; Eva Mm Strijbis; Bernard Mj Uitdehaag; Joep Killestein
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(5):593-600.
2012: Lisanne J Balk; Joep Killestein; Chris H Polman; Bernard M J Uitdehaag; Axel Petzold
Microcystic macular oedema confirmed, but not specific for multiple sclerosis.
Brain : a journal of neurology 2012;135(Pt 12):e226; author reply e227.
2012: Charlotte E Teunissen; Frederik Barkhof; Joep Killestein; C H Polman; M Sombekke; Lisa van Winsen; M A Blankenstein; Christine D Dijkstra; D Pratico
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(8):1092-8.
2012: Theo Rispens; Anke Vennegoor; Gert Jan Wolbink; Chris H Polman; Joep Killestein
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(6):899-901.
2012: Katja Herges; Joep Killestein; Rose M Ko; Ilan Kolkowitz; Alexander Maini; Gil Mandelbaum; Chris Polman; Lawrence Steinman; Brigit A de Jong; Caitlin Dunn; Jeffrey Dunn; Alexandra L Goodyear; May H Han; Robert C Axtell
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(4):398-408.
2012: Lisanne J Balk; Joep Killestein; Chris H Polman; Judith M Sonder; Eva M M Strijbis; Jos W R Twisk; Bernard M J Uitdehaag; Axel Petzold
The physiological variation of the retinal nerve fiber layer thickness and macular volume in humans as assessed by spectral domain-optical coherence tomography.
Investigative ophthalmology & visual science 2012;53(3):1251-7.
2011: Immy A Ketelslegers; Joep Killestein; Piet W Modderman; Anke Vennegoor; Dörte Hamann; Rogier Q Hintzen
Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients.
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(12):1527-30.
2011: Joep Killestein; Richard A Rudick; Chris H Polman
Oral treatment for multiple sclerosis.
Lancet neurology 2011;10(11):1026-34.
2011: Margreet H Hart; Joep Killestein; Lucien A Aarden; Els R de Groot; Henk de Vrieze; Gerrit-Jan Wolbink; Diana Wouters; Theo Rispens
Differential effect of drug interference in immunogenicity assays.
Journal of immunological methods 2011;372(1-2):196-203.
2011: S Vosslamber; T C T M van der Pouw Kraan; C Aubin; M Comabella; J B A Crusius; P L De Jager; D A Hafler; Roel Heijmans; Joep Killestein; X Montalban; C H Polman; B M J Uitdehaag; I J van den Elskamp; T C T M van der PouwKraan; L F van der Voort; Cornelis L Verweij
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.
Genes and immunity 2011;12(6):466-72.
2011: M H Sombekke; L F van der Voort; H Guzel; A Salvador Peña; C H Polman; A Visser; Hugo Vrenken; J B A Crusius; J J Kragt; J M Nielsen; C B M Oudejans; Joep Killestein
Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(8):922-30.
2011: Li-Fen Lee; Robert Axtell; Brigit A de Jong; Jeanette Dilley; Winston Evering; Bora Han; Joep Killestein; Kathryn Logronio; Chris H Polman; Mathias Rickert; Jing Shi; Lawrence Steinman; Guang Huan Tu; Michael G Walker; Jessica Yu; John C Lin
IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis.
Science translational medicine 2011;3(93):93ra68.
2011: Charlotte E Teunissen; J C Knol; M J A Koel-Simmelink; T V Pham; M Khalil; Joep Killestein; J Nielsen; V Popescu; A Trentini; Hugo Vrenken; C D Dijkstra; C R Jimenez
Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(7):838-50.
2011: Theo Rispens; Astrid van Leeuwen; Anke Vennegoor; Joep Killestein; Rob C Aalberse; Gertjan Wolbink; Lucien A Aarden
Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.
Analytical biochemistry 2011;411(2):271-6.
2011: Joep Killestein; Chris H Polman
Determinants of interferon β efficacy in patients with multiple sclerosis.
Nature reviews. Neurology 2011;7(4):221-8.
2011: A Vennegoor; Mike P Wattjes; E T L van Munster; R L Kriekaart; Bob W van Oosten; Frederik Barkhof; Joep Killestein; Chris H Polman
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
Neurology 2011;76(6):574-6.
2011: Charlotte E Teunissen; Hayrettin Tumani; Vincent van Pesch; Emmanuelle Waubant; Christian Wolf; Jeffrey L Bennett; Frode S Berven; Lou Brundin; Manuel Comabella; Florian Deisenhammer; Jette L Federiksen; John O Fleming; Diego Franciotta; Roberto Furlan; Gavin Giovannoni; Rogier Q Hintzen; Steven Hughes; Connie R Jimenez; Michael H Johnson; Joep Killestein; Eva Krasulova; Jens Kuhle; Maria Chiara Magnone; Axel Petzold; Cecilia Rajda; Konrad Rejdak; Hollie K Schmidt; Bernhard Hemmer
Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies.
Multiple sclerosis international 2011;2011():246412.
2010: V Worthington; Joep Killestein; M Judith Eikelenboom; Charlotte E Teunissen; Frederik Barkhof; Chris H Polman; B M J Uitdehaag; Axel Petzold
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency.
Neurology 2010;75(18):1617-22.
2010: L F van der Voort; A Vennegoor; A Visser; D L Knol; B M J Uitdehaag; Frederik Barkhof; C B M Oudejans; Chris H Polman; Joep Killestein
Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS.
Neurology 2010;75(14):1228-33.
2010: Joep Killestein; Anke Vennegoor; Eva M Strijbis; Alexandra Seewann; Bob W van Oosten; Bernard M J Uitdehaag; Chris H Polman
Natalizumab drug holiday in multiple sclerosis: poorly tolerated.
Annals of neurology 2010;68(3):392-5.
2010: Chris H Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Joep Killestein; Henry McFarland; Joel Oger; Andrew R Pachner; John Petkau; Anthony T Reder; Stephen C Reingold; Huub Schellekens; Per Soelberg Sørensen
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Lancet neurology 2010;9(7):740-50.
2010: Madeleine H Sombekke; David Arteta; Mark A van de Wiel; J B A Crusius; Diego Tejedor; Joep Killestein; Antonio Martínez; A Salvador Peña; Chris H Polman; Bernard M J Uitdehaag
Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2010;16(6):652-9.
2010: Gijs Kooij; Jack van Horssen; Elizabeth C M de Lange; Arie Reijerkerk; Susanne M A van der Pol; Bert Van het Hof; Joost Drexhage; Anke Vennegoor; Joep Killestein; George Scheffer; Ruud Oerlemans; Rik Scheper; Paul Van Der Valk; Christine D Dijkstra; Helga E de Vries
T lymphocytes impair P-glycoprotein function during neuroinflammation.
Journal of autoimmunity 2010;34(4):416-25.
2010: Robert C Axtell; Brigit A de Jong; Katia Boniface; Laura F van der Voort; Roopa Bhat; Patrizia De Sarno; Rodrigo Naves; May Han; Franklin Zhong; Jim G Castellanos; Robert Mair; Athena Christakos; Ilan Kolkowitz; Liat Katz; Joep Killestein; Chris H Polman; René de Waal Malefyt; Lawrence Steinman; Chander Raman
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Nature medicine 2010;16(4):406-12.
2010: Laura F van der Voort; Francesca Gilli; Antonio Bertolotto; Dirk L Knol; Bernard M J Uitdehaag; Chris H Polman; Joep Killestein
Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
Archives of neurology 2010;67(4):402-7.
2009: Madeleine H Sombekke; Carsten Lukas; J B A Crusius; Diego Tejedor; Joep Killestein; David Arteta; Antonio Martínez; Bernard M J Uitdehaag; Dirk L Knol; Amado Salvador Peña; Jeroen J G Geurts; Philip L De Jager; Frederik Barkhof; Hugo Vrenken; Chris H Polman
HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis.
Archives of neurology 2009;66(12):1531-6.
2009: M Judith Eikelenboom; Joep Killestein; J Jolijn Kragt; B M J Uitdehaag; Chris H Polman
Gender differences in multiple sclerosis: cytokines and vitamin D.
Journal of the neurological sciences 2009;286(1-2):40-2.
2009: M H J Vogt; Charlotte E Teunissen; E Iacobaeus; D A M Heijnen; E C W Breij; T Olsson; L Brundin; Joep Killestein; Christine D Dijkstra
Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2009;80(10):1110-5.
2009: L F van der Voort; A Visser; Dirk L Knol; C B M Oudejans; Chris H Polman; Joep Killestein
Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2009;16(9):1049-52.
2009: Nicolaas A Verwey; Nicolaas Verwey; Harry A M Twaalfhoven; Dorine Wouters; Jeroen J M Hoozemans; Yves J M Bollen; Joep Killestein; Mirko Bibl; Jens Wiltfang; C Erik Hack; Philip scheltens; Marinus A Blankenstein
Quantification of amyloid-beta 40 in cerebrospinal fluid.
Journal of immunological methods 2009;348(1-2):57-66.
2009: Aran F Labrijn; Antonio Ortiz Buijsse; Ewald T J van den Bremer; Annemiek Y W Verwilligen; Wim K Bleeker; Susan J Thorpe; Joep Killestein; Chris H Polman; Rob C Aalberse; Janine Schuurman; Jan G J van de Winkel; Paul W H I Parren
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.
Nature biotechnology 2009;27(8):767-71.
2009: Joep Killestein; jasperse bas; M Liedorp; A Seewann; Ch Polman
Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies.
Multiple sclerosis (Houndmills, Basingstoke, England) 2009;15(4):525-6.
2009: L F van der Voort; A Kok; A Visser; C B M Oudejans; M Caldano; F Gilli; A Bertolotto; Chris H Polman; Joep Killestein
Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
Multiple sclerosis (Houndmills, Basingstoke, England) 2009;15(2):212-8.
2009: Joep Killestein; Chris H Polman
[Alemtuzumab in early multiple sclerosis].
Nederlands tijdschrift voor geneeskunde 2009;153(1-2):46.
2008: Charlotte E Teunissen; Joep Killestein; J Jolijn Kragt; Chris H Polman; Christine D Dijkstra; H J Blom
Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2008;79(12):1349-53.
2008: Joep Killestein; Hans-Peter Hartung
Interferon beta in multiple sclerosis: predicting response at an early stage.
Journal of neurology, neurosurgery, and psychiatry 2008;79(6):616-7.
2008: Esther S Korf; Joep Killestein
Prednisolone or acyclovir in Bell's palsy.
The New England journal of medicine 2008;358(3):306-7; author reply 307.
2008: Lisa G M van Baarsen; Saskia Vosslamber; Marianne Tijssen; Josefien M C Baggen; Laura F van der Voort; Joep Killestein; Tineke C T M van der Pouw Kraan; Chris H Polman; Cornelis L Verweij
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
PloS one 2008;3(4):e1927.
2008: Rachel Farrell; Klaus Bendtzen; Antonio Bertolotto; Berwyn Clark; Manuel Comabella; Florian Deisenhammer; Anna Fogdell-Hahn; Gavin Giovannoni; Hans Peter Hartung; Bernard Hemmer; Jan Hillert; Ludwig Kappos; Joep Killestein; Raija Lindberg; Xavier Montalban; Chris Polman; Per Soelberg Sorensen
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
The Journal of international medical research 2008;36(1):204-8; author reply 208-10.
2007: Chris H Polman; Florian Deisenhammer; Gavin Giovannoni; Joep Killestein; Huub Schellekens
Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Neurology 2007;69(15):1553-4; author reply 1555.
2007: M Liedorp; E Sanchez; I M W van Hoogstraten; B Mary E von Blomberg; Frederik Barkhof; Chris H Polman; Joep Killestein
No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up.
Journal of neurology, neurosurgery, and psychiatry 2007;78(10):1146-8.
2007: Hans-P Hartung; Chris H Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Eva Havrdova; Bernhard Hemmer; Jan Hillert; Ludwig Kappos; Bernd C Kieseier; Joep Killestein; Christophe Malcus; Manuel Comabella; Andrew R Pachner; Huub Schellekens; Finn Sellebjerg; Krzysztof Selmaj; Per Soelberg Sorensen
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Journal of neurology 2007;254(7):827-37.
2007: Bernard Uitdehaag; Brechtje Jelles; Joep Killestein; Bob W van Oosten; Chris H Polman
[Immunomodulatory therapy in multiple sclerosis].
Nederlands tijdschrift voor geneeskunde 2007;151(25):1435; author reply 1435-6.
2007: Charlotte E Teunissen; Joep Killestein; Gavin Giovannoni
Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity.
Biomarkers in medicine 2007;1(1):111-9.
2006: Chris H Polman; Huub Schellekens; Joep Killestein
Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(3):245-6.
2005: Joep Killestein; Bernard Uitdehaag
Cannabinoids in multiple sclerosis: urgent need for long term trials.
Journal of neurology, neurosurgery, and psychiatry 2005;76(12):1612.
2005: M Judith Eikelenboom; Joep Killestein; Bernard Uitdehaag; Chris H Polman
Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(5):520-3.
2005: Joep Killestein; Nynke F Kalkers; Chris H Polman
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
Journal of the neurological sciences 2005;233(1-2):113-5.
2005: Joep Killestein; Chris H Polman
Current trials in multiple sclerosis: established evidence and future hopes.
Current opinion in neurology 2005;18(3):253-60.
2005: Joep Killestein
Carotid-artery stenting versus endarterectomy.
The New England journal of medicine 2005;352(6):624-7; author reply 624-7.
2005: M Judith Eikelenboom; Joep Killestein; Thijs Izeboud; Nynke F Kalkers; Paul A Baars; René A W van Lier; Frederik Barkhof; Bernard Uitdehaag; Chris H Polman
Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.
Journal of neuroimmunology 2005;158(1-2):222-30.
2004: Joep Killestein; PM Bet; Andre C D van Loenen; Chris H Polman
[Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness].
Nederlands tijdschrift voor geneeskunde 2004;148(48):2374-8.
2004: Mario H J Vogt; Sarah Floris; Joep Killestein; Dirk L Knol; Monique Smits; Frederik Barkhof; Chris H Polman; Lex Nagelkerken
Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients.
Journal of neuroimmunology 2004;155(1-2):155-60.
2004: Joep Killestein; Chris H Polman
The therapeutic value of cannabinoids in MS: real or imaginary?
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(4):339-40.
2004: M Judith Eikelenboom; Joep Killestein; Bernard Uitdehaag; Chris H Polman
Opticospinal multiple sclerosis: a pathogenetically distinct form?
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(3):334-5.
2004: Bob W van Oosten; Joep Killestein; E M H Mathus-Vliegen; Chris H Polman
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(3):330-1.
2004: Chris H Polman; Joep Killestein
Statins for the treatment of multiple sclerosis: cautious hope.
Lancet 2004;363(9421):1570.
2004: Sarah Floris; Annette van der Goes; Joep Killestein; Dirk L Knol; Frederik Barkhof; Chris H Polman; Christine D Dijkstra; Helga E de Vries; Jan F Meilof
Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels.
Journal of neuroimmunology 2004;148(1-2):172-7.
2004: Joep Killestein; Bernard Uitdehaag; Chris H Polman
Cannabinoids in multiple sclerosis: do they have a therapeutic role?
Drugs 2004;64(1):1-11.
2003: Joep Killestein; M Judith Eikelenboom; Thijs Izeboud; Nynke F Kalkers; Herman J Adèr; Frederik Barkhof; René A W van Lier; Bernard Uitdehaag; Chris H Polman
Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.
Journal of neuroimmunology 2003;142(1-2):141-8.
2003: Joep Killestein; Bernard Uitdehaag; Chris H Polman
Cannabinoids and immune function.
JAMA : the journal of the American Medical Association 2003;290(6):754; author reply 755.
2003: Joep Killestein; Chris H Polman
Cannabis use in multiple sclerosis: excited interest.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2003;30(3):181-2.
2003: Joep Killestein
ASCOT-LLA: questions about the benefits of atorvastatin.
Lancet 2003;361(9373):1986; author reply 1986-7.
2003: Joep Killestein; E L J Hoogervorst; Marcus Reif; Bep Blauw; Monique Smits; Bernard Uitdehaag; Lex Nagelkerken; Chris H Polman
Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis.
Journal of neuroimmunology 2003;137(1-2):140-3.
2002: M Judith Eikelenboom; Joep Killestein; Thijs Izeboud; Nynke F Kalkers; René A W van Lier; Frederik Barkhof; Bernard Uitdehaag; Chris H Polman
Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis.
Journal of neuroimmunology 2002;133(1-2):225-32.
2002: Joep Killestein; Rogier Q Hintzen; Bernard Uitdehaag; Paul A Baars; Marijke Th L Roos; René A W van Lier; Chris H Polman
Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta.
Journal of neuroimmunology 2002;133(1-2):217-24.
2002: Joep Killestein
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
The New England journal of medicine 2002;347(14):1116-7; author reply 1116-7.
2002: Joep Killestein; E L J Hoogervorst; Marcus Reif; Nynke F Kalkers; Andre C D van Loenen; P G M Staats; Robert W Gorter; Bernard Uitdehaag; Chris H Polman
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Neurology 2002;58(9):1404-7.
2002: Joep Killestein; Martijn Rep; Jan F Meilof; Herman J Adèr; Bernard Uitdehaag; Frederik Barkhof; René A W van Lier; Chris H Polman
Seasonal variation in immune measurements and MRI markers of disease activity in MS.
Neurology 2002;58(7):1077-80.
2002: Joep Killestein; Tomas Olsson; Erik Wallström; Anders Svenningsson; Mohsen Khademi; Lance D Blumhardt; Jan Fagius; Jan Hillert; Anne-Marie Landtblom; Charlotte Edenius; Leopold Arfors; Frederik Barkhof; Chris H Polman
Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial.
Annals of neurology 2002;51(4):467-74.
2001: Anette H H van Boxel-Dezaire; Monique Smits; S C van Trigt-Hoff; Joep Killestein; Johannes C van Houwelingen; Chris H Polman; Lex Nagelkerken
Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis.
Journal of neuroimmunology 2001;120(1-2):152-60.
2001: Joep Killestein; Nynke F Kalkers; Jan F Meilof; Frederik Barkhof; René A W van Lier; Chris H Polman
TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.
Neurology 2001;57(6):1129-31.
2001: Joep Killestein; Martijn Rep; Frederik Barkhof; Marijke Th L Roos; Herman J Adèr; René A W van Lier; Chris H Polman
Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells.
Journal of neuroimmunology 2001;118(2):286-94.
2001: Tineke Van Veen; J B Crusius; Hans M Schrijver; G Bouma; Joep Killestein; Lisa van Winsen; A Salvador Peña; Chris H Polman; Bernard Uitdehaag
Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis.
Annals of neurology 2001;50(2):275.
2001: Joep Killestein; B F Den Drijver; W L Van der Graaff; Bernard Uitdehaag; Chris H Polman; René A W van Lier
Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(3):145-50.
2001: S A Morré; J van Beek; Christianne J M De Groot; Joep Killestein; C J Meijer; Chris H Polman; Paul Van Der Valk; Jaap Middeldorp; A J van Den Brule
Is Epstein-Barr virus present in the CNS of patients with MS?
Neurology 2001;56(5):692.
2000: J H Arnoldus; Joep Killestein; Lilian E M A Pfennings; Brechtje Jelles; Bernard Uitdehaag; Chris H Polman
Quality of life during the first 6 months of interferon-beta treatment in patients with MS.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(5):338-42.
2000: Anette H H van Boxel-Dezaire; S C van Trigt-Hoff; Joep Killestein; Hans M Schrijver; Johannes C van Houwelingen; Chris H Polman; Lex Nagelkerken
Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
Annals of neurology 2000;48(3):313-22.
2000: Nynke F Kalkers; Vincent de Groot; R H C Lazeron; Joep Killestein; Herman J Adèr; Frederik Barkhof; Gustaaf J Lankhorst; Chris H Polman
MS functional composite: relation to disease phenotype and disability strata.
Neurology 2000;54(6):1233-9.
2000: Joep Killestein; Hans M Schrijver; J B Crusius; C Pérez; Bernard Uitdehaag; A S Peña; Chris H Polman
Intracellular adhesion molecule-1 polymorphisms and genetic susceptibility to multiple sclerosis: additional data and meta-analysis.
Annals of neurology 2000;47(2):277-9.